Effect of Antioxidant Intake on Resistin Levels In Patients With Gum Disease and Diabetes (EARGD)

Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre

Status: Completed

Conditions: Periodontitis; Diabetes Mellitus

Treatments: Procedure: Scaling and Root planing; Other: Alpha lipoic acid

Study type: Interventional

Funder types: Other

Identifiers

NCT02775266

00159

Details and patient eligibility

About

To evaluate the effectiveness of non surgical periodontal therapy in addition to antioxidant(ALA) on resistin levels in patients with type 2 diabetes and periodontal disease

Full description

A total of 40 patients with diabetes and chronic periodontitis attending the department of periodontics will be recruited in the study. 40 subjects will be randomly divided into two groups(control group and test group with 20 subjects in each group). Clinical parameters such as gingival index, periodontal index, random blood sugar levels(RBS) and glycosylated hemoglobin levels (Hb1aC) will be recorded at baseline and after 3 months and 2ml of blood sample will be collected by venepuncture ( baseline and after 3 months) and stored in Ethylenediaminetetraacetic acid containing vials to identify the levels of resistin in the patients by Enzyme linked immunosorbent assay. Group A will receive Alpha lipoic acid at baseline for a period of 3 months. Both the groups will receive scaling and rootplaning at baseline.

Enrollment: 40 patients

Sex: All

Ages: 35 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Diabetic patients with Chronic periodontitis.

Exclusion Criteria: Smokers, Pregnant & lactating women, Prior periodontal therapy within 3 months.

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

40 participants in 2 patient groups, including a placebo group

ALA + Scaling and Root planing

Active Comparator group

Description:

Systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months(group B)

Treatment:

Procedure: Scaling and Root planing

Other: Alpha lipoic acid

Scaling and root planing only

Placebo Comparator group

Description:

Patients will receive scaling and root planning at baseline and 3 months(group A)

Treatment:

Procedure: Scaling and Root planing